Psoriasis Clinical Trials


ESPRIT Chronic Plaque Psoriasis Registry – ACTIVE/NOT ENROLLING

  • ESPRIT is a 10 year registry of patients taking HUMIRA® for Psoriasis. Patients who volunteer to participate will be asked to provide information about their medical history and experiences with HUMIRA®. No registry specific testing will be performed. Patients will be asked to provide data on their experiences with HUMIRA® approximately every 6 months, or as determined by the study doctor. No drug will be provided as a result of participation in the registry. All treatment decisions are independent of participation in the registry. This is an ongoing trial, but we are no longer enrolling.

Corrona Protocol PSO-500: A study of the comparative safety of approved psoriasis therapies in a national cohort of psoriasis subjects treated by dermatologists – ACTIVE/CURRENTLY ENROLLING

  • A Phase IV observational study that compares systemic psoriasis therapies that are available for prescription.

Celgene protocol 826652: A Phase IV, open label study of the effects of apremilast on vascular inflammation and cardiometabolic function in psoriasis  – ACTIVE/NOT ENROLLING

  • An open label study of apremilast in adult patients with moderate to severe plaque psoriasis.

Lilly protocol I6T-MC-AMAH: A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis – ACTIVE/NOT ENROLLING

  • A phase III trial investigating an il-23 inhibitor in adult patients with moderate to severe plaque psoriasis who have previously completed participation in I6T-MC-AMAH.

Abbvie protocol M19-164: A Phase 3b, Multicenter, Interventional, Open-label Study of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Have a Suboptimal Response to Secukinumab or Ixekizumab and Are Switched to Risankizumab – CURRENTLY ENROLLING

  • A Phase 3b study for patients who have failed il-17 inhibitors, investigating risankizumab.

Corrona Psoriasis Registry

  • Any adult patient who started a biologic therapy in the past year, or is being prescribed a biologic therapy, is eligible! Patients come to the Rockville office every 6 months for 8 years, and will receive a $25 gift card


  • Adult patients who have failed Cosentyx or Taltz could be eligible to participate in this open-label study investigating Skyrizi. 1 year of treatment at no cost to patients!

The Clinical Research team at DermAssociates is committed to conducting clinical research in accordance with Good Clinical Practices and IHCP guidelines to ensure the trials are carried out safely and ethically. DermAssociates consistently seeks optimal results for its patients and has a proven record of meeting and exceeding expectations.